(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 September 2025 (04.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/184661 A1

(51) International Patent Classification:
A61K 31/7088 (2006.01) *C07H 21/04* (2006.01)
C07H 21/02 (2006.01) *C12N 15/113* (2010.01)

(21) International Application Number:
PCT/US2025/018204

(22) International Filing Date:
03 March 2025 (03.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/560,561	01 March 2024 (01.03.2024)	US
63/636,435	19 April 2024 (19.04.2024)	US
63/691,219	05 September 2024 (05.09.2024)	US
63/714,071	30 October 2024 (30.10.2024)	US

(71) Applicant: **WAVE LIFE SCIENCES LTD.** [SG/SG]; 7 Straits View #12-00, Marina One East Tower, Singapore 018936 (SG).

(72) Inventors; and

(71) Applicants *(for US only)*: **VARGEESE, Chandra** [US/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **IWAMOTO, Naoki** [JP/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **LIU, Wei** [CN/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **SHAH, Himali, Kavin** [IN/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **MERRILL, Erin** [US/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **KANDASAMY, Pachamuthu** [US/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **MARAPPAN, Subramanian** [US/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **KUMARASAMY, Jayakanthan** [CA/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **CHATTERJEE, Arindom** [IN/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **OWEN, Adriana, Lourdes** [US/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **LIU, Siqi** [CN/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **LUU, Khoa, Ngoc Dang** [VN/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US). **BYRNE, Michael, John** [CA/US]; c/o Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 (US).

(74) Agent: **LENDARIS, Steven, P.**; Baker Botts LLP, 30 Rockefeller Plaza, New York, NY 10112-4498 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2025/184661 A1

(54) Title: DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO

(57) Abstract: The present disclosure provides double stranded oligonucleotides, compositions, and methods relating thereto wherein the oligonucleotides comprise modifications of internucleotidic linkages. The present disclosure encompasses the recognition that structural elements of double stranded oligonucleotides, such as base modifications, as well as base sequence, chemical modifications (e.g., modifications of sugar and/or internucleotidic linkages) or patterns thereof, and/or stereochemistry, e.g., stereochemistry of chiral internucleotidic linkages, and/or patterns thereof, can have significant impact on oligonucleotide properties, e.g., RNA interference activity. The present disclosure also provides methods for treatment of diseases, e.g., hepatic diseases, central nervous system diseases, etc., using the provided double stranded oligonucleotide compositions.